Back
Compare AU
Compare FANG vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X Fang+ ETF (FANG) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
FANG | CURE | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 1,896 | 70 |
Median incremental investment | $993.50 | $684.93 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,160.96 | $2,111.53 |
Average age group | > 35 | > 35 |
Key Summary
FANG | CURE | |
|---|---|---|
Strategy | The Global X FANG+ ETF (FANG) seeks to track the performance of the NYSE FANG+® Index before fees, expenses, and taxes. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Micron Technology Inc (18.51 %) Broadcom Inc (10.48 %) Apple Inc (10.15 %) | TG Therapeutics Inc (2.00 %) Travere Therapeutics Inc Ordinary Shares (1.93 %) Alkermes PLC (1.89 %) |
Top 3 industries | Information Technology (59.88 %) Communication Services (30.22 %) Consumer Discretionary (9.90 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (100.00 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0.35 % | 0.45 % |
Key Summary
FANG | CURE | |
|---|---|---|
Issuer | ETFS | Global X |
Tracking index | NYSE FANG+ Index | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.35 % | 0.45 % |
Price | $36.56 | $64.97 |
Size | $1.628 billion | $40.191 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 7.29 % | 5.08 % |
Market | ASX | ASX |
First listed date | 02/03/2020 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
FANG | CURE | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 1,896 | 70 |
Median incremental investment | $993.50 | $684.93 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,160.96 | $2,111.53 |
Average age group | > 35 | > 35 |
Pros and Cons
FANG | CURE | |
|---|---|---|
Pros |
| |
Cons |
|
FANG | CURE |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |